Congenica clinches Portugal genome project
Cambridge digital healthcare specialist Congenica has revealed a new customer partnership with a leading paediatric hospital in Portugal.
Coimbra Paediatric Hospital will use Congenica’s Sapientia™ software platform to perform analysis of whole-exome sequencing data and produce diagnostic reports for its €1.2 million Portuguese In2Genome project.
Congenica says this new partnership underlines the clinical value of Sapientia for fast and accurate diagnoses in paediatrics and rare diseases on a global scale.
The deal builds on Congenica’s involvement with Genomics England’s 100,000 Genomes Project and China’s 100,000 Wellness Program. In April, Cambridge-based Congenica announced three new Chinese investors at the close of its Series B fundraising round.
Sérgio B. Sousa, medical geneticist at CPH, said: “This is a unique and innovative project for the Portuguese national health system. We have chosen Sapientia due to its demonstrated speed and high accuracy in other diagnostic projects as well as the well-known UK 100K Genomes Project.
“One of the main aims of In2Genome will be to set up a whole-exome sequencing analysis service at our leading public hospital centre. Our first project is the study of a large cohort of patients with neurodevelopmental disorders, namely intellectual disability syndromes with the aim of developing faster precise diagnostics to better support patient’s health and lifestyle outcomes.”
Sapientia is currently deployed at a number of clinical and research organisations as well as being used for the interpretation of rare disease in the 100,000 Genomes Project.
Led by CEO Tom Weaver (pictured), Congenica raised $10m in February in its Series B financing round. Existing investors, Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners (Amadeus) participated alongside new investor, Parkwalk Advisors.